Merus N.V. (MRUS) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Utrecht, Netherlands. 현재 CEO는 Jan van de Winkel.
MRUS 을(를) 보유 IPO 날짜 2016-05-19, 260 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $6.83B.
Merus N.V. is a clinical-stage immuno-oncology company headquartered in Utrecht, the Netherlands, focused on discovering and developing bispecific antibody therapeutics. The company's pipeline includes several candidates in various development stages, notably Zenocutuzumab (MCLA-128) in Phase 2 trials for metastatic breast cancer, along with MCLA-158, MCLA-145, MCLA-129, and ONO-4685 in Phase 1 or Phase 1/2 trials for various solid tumors and hematologic malignancies. Merus has established strategic collaborations with Betta Pharmaceuticals and Incyte Corporation to advance select candidates in its portfolio. Founded in 2003, the company leverages its bispecific antibody platform to develop novel cancer therapeutics targeting multiple pathways simultaneously.
